Clinical trial

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent…

NCT00369954 · Gynecologic Oncology Group, Other · Withdrawn

Key facts

NCT number NCT00369954
Title Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
Official title A Phase II Trial of Intravenous Gemcitabine (NSC #613327) and Intraperitoneal Carboplatin (NSC # 241240) in the Treatment of Patients With Platinum-Sensitive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma With Non-Measurable Disease
Lead sponsor Gynecologic Oncology Group, Other
Collaborators National Cancer Institute (NCI) NIH
Status Withdrawn
Phase Phase 2
Study type Interventional
Conditions Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Intervention type Drug
Interventions carboplatin, gemcitabine hydrochloride
Enrollment 0
Start date Apr 1, 2006
First posted Aug 30, 2006
Last update posted Jun 10, 2013

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies